Insider · CIK 0001157075

PharmaCyte Biotech, Inc.

owner

Files at QCLS (Q/C TECHNOLOGIES, INC.), FEMY (FEMASYS INC). First filing -, latest -.

In brief

PharmaCyte Biotech, Inc. files SEC Form 4 as 10% owner at QCLS (Q/C TECHNOLOGIES, INC.), and also at FEMY (FEMASYS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; PharmaCyte Biotech, Inc. has 0, so none is measured yet.

Track record

Not enough history

Fewer than three past buys with six months of prices.

Median 6-month excess

after past buys, n = 0

Hit rate

past buys that beat the index over 6 months

Open-market trades

0 / 0

$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

Date	Company	Transaction	Shares	Price	Value	Holdings after	Filed
Sep 4, 2025	QCLS Q/C TECHNOLOGIES, INC.	POpen-market purchase Series H Convertible Preferred Stockderivative	+889,865	-	-	889,865	Nov 18, 2025
Nov 14, 2025	QCLS Q/C TECHNOLOGIES, INC.	POpen-market purchase Warrantsderivative	+889,865	-	-	889,865	Nov 18, 2025

Questions about PharmaCyte Biotech, Inc.

Answered from the filings on this page, as of the latest one.

Is PharmaCyte Biotech, Inc. buying or selling?

PharmaCyte Biotech, Inc. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did PharmaCyte Biotech, Inc.'s past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and PharmaCyte Biotech, Inc. has 0.

Where does PharmaCyte Biotech, Inc. file Form 4?

PharmaCyte Biotech, Inc. has filed Form 4 at QCLS (Q/C TECHNOLOGIES, INC.); FEMY (FEMASYS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.